RecruitingPhase 1NCT06204835

ITGA6 Targeting NIR-II Fluorescence Image Guided Surgery

ITGA6 Targeting NIR-II Fluorescence Image Guided Surgery of HCC Patients


Sponsor

Institute of Automation, Chinese Academy of Sciences

Enrollment

90 participants

Start Date

Jan 7, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

In this study, the investigators will detect hepatocellular carcinoma lesions using fluoescence imaging with ITGA6 targeting probes during tumor resection surgery. The aim is to evaluate wether intraoperative fluorescence imaging targeting ITGA6 can help to improve the detction effect of hepatocellular carcinoma, and finally help the accurate surgical resection. The main purposes of this study include: 1. To raise the detection rate of hepatocellular carcinoma intraoperatively using the novel NIR-II fluorescence molecular imaging and the ITGA6 targeting probe. 2. To validate the safety and effectiveness of the proposed ITGA6 targeting probes for clinical application.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria6

  • Patients who have been diagnosed with hepatocellular carcinoma.
  • Planned to receive hepatectomy.
  • Liver function Child-Pugh A.
  • ITGA6 was validated highly expressed preoperatively.
  • Aged 18 to 80, and the expected lifetime is longer than 6 months.
  • Approved to sign the informed consent.

Exclusion Criteria6

  • Allergic to Cy7.
  • Enrolled in other trials in the past 3 months.
  • Another malignant tumor was found.
  • Undesirable function of heart, lung, kidney, or any other organs.
  • Unable to tolerate a hepatectomy.
  • The researchers considered inappropriate to be included.

Interventions

DRUGRD-Cy7 fluorophore

Fluorophore targeting ITGA6 that is overexpressed in HCC cells


Locations(2)

Guangdong

Guangzhou, Guangdong, China

Sichuan

Luzhou, Sichuan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06204835


Related Trials